About Thalassemia
Thalassemia is an inherited blood disorder that predominantly affects the iron levels in the red blood cells. There are two types of drugs for the treatment of thalassemia, alpha thalassemia drugs and beta thalassemia drugs.
’s analysts forecast the Global Thalassemia Drugs Market to grow at a CAGR of 9.9% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the thalassemia drugs market. To calculate the market size, the report considers the revenue generated from the retail sales of alpha thalassemia drugs and beta thalassemia drugs across the globe.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

's report, thalassemia drugs market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• ApoPharma
• Fresenius Kabi
• Novartis
• Pfizer
• Teva Pharmaceutical Industries
Market driver
• Increasing prevalence of thalassemia
• For a full, detailed list, view our report

Market challenge
• High expense of treatment
• For a full, detailed list, view our report

Market trend
• Rising disease awareness programs
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.